A Southern California biopharmaceutical company has announced positive data from a phase 1/2 clinical trial of its proprietary monoclonal antibody, AOC 1001, for those with myotonic dystrophy type 1.
According to a release from Avidity Biosciences, data from the MARINA study and its open-label extension, MARINA-OLE, which was presented at the 28th Annual Congress of the World Muscle Society in South Carolina, found treatment with the novel therapeutic led to improved functional measures including hand grip, muscle strength and patient reported outcomes. The new data bolsters previously